Rhythmic drug dosing may boost safety and efficacy in chronic liver disease

Metabolic dysfunction-associated steatohepatitis (MASH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are progressive chronic liver diseases linked to abnormal bile acid metabolism. Although these diseases differ in origin, they all lead to a similar outcome: abnormal hepatic accumulation of bile acids and liver injury.